News MSD aims to plug dengue fever vaccine gap in US MSD is preparing to take on Takeda in the dengue fever vaccine market, moving its V181 candidate into phase 3.
News Takeda scores with polycythemia vera drug in phase 3 trial A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.
News Takeda CEO succession confirmed as Weber plans retirement Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.
News Takeda backs biomarker trial for Crohn's prevention The INTERCEPT trial aims to validate biomarkers that could identify people at risk of Crohn's and see if treatment can prevent symptoms developing.
Sales & Marketing Sponsored Go slow to go fast: Setting a content transformation journey... Pharma marketing is evolving and it’s evolving quickly. How can organisations successfully ride the wave of this transformation?
News NICE turns down Takeda colorectal cancer drug Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the grounds that it is not cost-effective.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
